Company / Financials
Candel Therapeutics, Inc. Financials
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
-
FY2023
Net Income
-$37.9M
FY2023 · -5.0% YoY
Profit Margin
-
FY2023 · net income / revenue
ROE
-297.7%
FY2023 · return on equity
Total Assets
$41.2M
FY2023
Total Debt
$11.6M
0.91x debt/equity
Equity
$12.7M
FY2023
ROA
-92.1%
FY2023 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations-Net Income HistoryProfit after all expenses and taxes-$37.9M-5.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$38.4M-49.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$13.9M+30.1% YoYR&D Expense HistoryResearch and development spending$24.5M+61.5% YoYInterest Expense HistoryCost of borrowing and debt obligations-$2.6MIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.65+66.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.65+66.0% YoYShares Outstanding HistoryWeighted average diluted shares outstanding28.9M+0.8% YoY